Print

BioLineRx Ltd. In-Licenses BL-3010 From Gevys Pharmaceuticals For The Treatment Of Pain And Plans To Initiate Phase I/II Trial  
5/25/2006 5:15:26 PM

BioLineRx, Ltd., Israel's leading drug development company, today announced that it has signed an exclusive worldwide licensing agreement with Gevys Pharmaceuticals Ltd. for the development and commercialization of BL-3010, a novel approach for the treatment of acute and chronic pain. Gevys's patented technology utilizes a combination of approved drugs to dramatically increase the potency of micro-doses of classical pain medications. The result is that BL-3010 will deliver effective pain relief with significant reductions in toxicity and side effects.
//-->